Target Name: DBIL5P2
NCBI ID: G100169989
Review Report on DBIL5P2 Target / Biomarker Content of Review Report on DBIL5P2 Target / Biomarker
DBIL5P2
Other Name(s): ELP1P | Diazepam binding inhibitor-like 5 pseudogene 2 | diazepam binding inhibitor-like 5 pseudogene 2

DBIL5P2: A Potential Drug Target and Biomarker

DBIL5P2, short for double-stranded RNA-binding proteins-related introns 5 and 2, is a gene that encodes a protein known to localize to the nuclear matrix. The nuclear matrix is a protein-rich structure that organizes the nuclear chromosomes and plays a crucial role in various cellular processes, including DNA replication, gene expression, and chromatin regulation. As a protein that is involved in the nuclear matrix, DBIL5P2 is a potential drug target and biomarker for a variety of diseases.

DBIL5P2: Structure and Function

DBIL5P2 is a 21-kDa protein that consists of two subunits, alpha and beta. The alpha subunit has a molecular weight of 42 kDa, while the beta subunit has a molecular weight of 21 kDa. DBIL5P2 is localized to the nuclear matrix and is involved in the organization of the nuclear chromosomes.

The nuclear matrix is a complex structure that consists of various proteins that help to maintain the integrity and organization of the chromosomes. DBIL5P2 is one of the proteins that is known to be involved in this process. Specifically, DBIL5P2 is involved in the localization of chromatin to the nuclear matrix and in the regulation of chromatin structure.

DBIL5P2 has been shown to play a role in the regulation of gene expression. In various cellular assays, DBIL5P2 has been shown to physically interact with specific DNA sequences and to regulate the activity of gene transcription factors. This suggests that DBIL5P2 may be a useful drug target for diseases that are characterized by disruptions in gene expression, such as cancer.

DBIL5P2 has also been shown to be involved in the regulation of chromatin structure. In various studies, DBIL5P2 has been shown to interact with the protein histone H3 and to regulate the level of histone tails at specific locations on the chromatin. This suggests that DBIL5P2 may be a useful drug target for diseases that are characterized by disruptions in chromatin structure, such as neurodegenerative diseases.

Drug Target Potential

DBIL5P2 is a potential drug target due to its involvement in the regulation of gene expression and chromatin structure. dbil5p2 functions as a negative regulator of gene expression, it can inhibit the activity of gene transcription factors, which play a crucial role in the regulation of gene expression. Therefore, inhibiting DBIL5P2 activity may be a promising approach for treating diseases that are characterized by disruptions in gene expression.

In addition, DBIL5P2 is involved in the regulation of chromatin structure, which is a critical factor in the development and progression of many diseases. Therefore, inhibiting DBIL5P2 activity may be a promising approach for treating diseases that are characterized by disruptions in chromatin structure.

Biomarker Potential

DBIL5P2 has the potential to serve as a biomarker for a variety of diseases. One of the main applications of DBIL5P2 is its potential as a drug target for cancer. DBIL5P2 has been shown to play a role in the regulation of gene expression and chromatin structure in cancer cells, which suggests that it may be a useful target for cancer therapies that target these processes.

In addition, DBIL5P2 may be used as a biomarker for neurological and psychiatric diseases. The regulation of chromatin structure is involved in the development and progression of many neurological and psychiatric diseases, including Alzheimer's disease, Parkinson's disease, and depression. Therefore, studying the role of DBIL5P2 in the regulation of chromatin structure may provide valuable insights into the underlying mechanisms of these diseases.

Conclusion

DBIL5P2 is a gene that encodes a protein involved in the nuclear matrix and the regulation of gene expression and chromatin structure. The regulation of chromatin structure is

Protein Name: Diazepam Binding Inhibitor-like 5 Pseudogene 2

The "DBIL5P2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DBIL5P2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.tech.

More Common Targets

DBIP2 | DBN1 | DBP | DBT | DBX1 | DCAF13P3 | DCC | DCHS2 | DCK | DCLK2 | DCN | DCP1B | DCP2 | DCST1-AS1 | DCT | DCTD | DCTN1 | DCTN1-AS1 | DCUN1D1 | DCX | DDB1 | DDB2 | DDC | DDC-AS1 | DDIT3 | DDOST | DDT | DDTL | DDX1 | DDX10 | DDX11 | DDX11-AS1 | DDX11L1 | DDX11L10 | DDX11L8 | DDX11L9 | DDX19A-DT | DDX3P1 | DDX3X | DDX4 | DDX49 | DDX5 | DDX50P1 | DDX53 | DDX56 | DDX6 | DECR1 | DEDD2 | DEF8 | DEFA1 | DEFA3 | DEFA4 | DEFA5 | DEFA6 | DEFB1 | DEFB108F | DEFB109C | DEFB118 | DEFB131B | DEFB4A | DEFB4B | DEFT1P | DEFT1P2 | DENND1B | DENND2C | DEPDC4 | DES | DFFA | DFFB | DGCR8 | DGKB | DGKG | DGKH | DGKQ | DGUOK | DGUOK-AS1 | DHCR24 | DHCR7 | DHFR | DHFRP3 | DHODH | DHPS | DHRS9 | DHX15 | DHX29 | DHX36 | DHX8 | DHX9 | DIAPH1 | DIAPH2 | DIAPH3-AS1 | DIO1 | DIO2 | DIO2-AS1 | DIO3 | DIP2A-IT1 | DIRAS2 | DKC1 | DLAT | DLD